1
|
Park JH, Jung KH, Vithayathil S, Jia D, Kaipparettu BA. Abstract P2-02-11: Combinational treatment of biguanides and fatty acid β-oxidation inhibitor in triple-negative breast cancers. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-02-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Among breast cancers (BCs), the driver pathways and therapeutic targets are still poorly understood for triple negative (TN) BCs. Advances in cancer metabolism research over the last decade have enhanced our understanding on metabolic reprogramming in cancer therapy. We have previously shown that metabolic reprogramming to fatty acid β-oxidation (FAO) is a major energy pathway in metastatic TNBC. Moreover, we reported that FAO regulates c-Src, one of the frequently upregulated oncopathways in TNBC via autophosphorylation of Src at Y419. Since FAO inhibitors alone cannot effectively control the tumor progression in TNBC, suitable combination therapies with other metabolic targets are necessary. Recently increasing evidences show that anti-diabetic biguanides have attractive anticancer effect in various cancer types including BC. However, its significance as an anticancer drug is not well established due to parallel metabolic pathways that support tumor growth.
Phenformin, a biguanide derivative similar to metformin, has a greater potency than metformin. Like metformin, phenformin also inhibits mitochondrial electron transport chain (ETC) through complex I inhibition. In addition, biguanides lead to the activation of AMPK, which plays a key role in insulin signaling and energy sensing. Importantly, AMPK is an upstream regulator of FAO pathway because it can phosphorylate ACC to activate FAO. Considering the dependency of TNBC to FAO, we evaluated the therapeutic significance of the combination of biguanides(ETC inhibitors) and FAO inhibitors in TNBC progression and metastasis. We hypothesize that blocking both 'arms' of the pathway can provide more pronounced and durable responses in TNBCs. Our different in vitro and in vivo studies using TNBC cell line and PDX models suggest that the combination of both inhibitors can provide better therapeutic significance in metastatic TNBCs. This is a rationale and cost-effective metabolic approach to manage the currently non-targetable metastatic TNBCs. Further investigation into the clinical effectiveness of this combination may provide better treatment opportunities for TNBC patients.
Citation Format: Park JH, Jung KH, Vithayathil S, Jia D, Kaipparettu BA. Combinational treatment of biguanides and fatty acid β-oxidation inhibitor in triple-negative breast cancers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-02-11.
Collapse
Affiliation(s)
- JH Park
- Baylor College of Medicine, Houston, TX; Center for Theoretical Biological Physics, Rice University, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| | - KH Jung
- Baylor College of Medicine, Houston, TX; Center for Theoretical Biological Physics, Rice University, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| | - S Vithayathil
- Baylor College of Medicine, Houston, TX; Center for Theoretical Biological Physics, Rice University, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| | - D Jia
- Baylor College of Medicine, Houston, TX; Center for Theoretical Biological Physics, Rice University, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| | - BA Kaipparettu
- Baylor College of Medicine, Houston, TX; Center for Theoretical Biological Physics, Rice University, Houston, TX; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
| |
Collapse
|
2
|
Park JH, Jung KH, Sirupangi T, Vithayathil S, Jin F, Putluri V, Piyarathna DWB, Yotnda P, Bhat VB, Sreekumar A, Lewis MT, Coarfa C, Putluri N, Creighton CJ, Wong LJC, Kaipparettu BA. Abstract P6-01-07: Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-01-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
For triple negative breast cancer (TNBC), the driver pathways are still poorly understood. Advances in cancer metabolism research over the last decade have enhanced and modified our understanding on Warburg effect. It is now known that mitochondria in tumors are not always defective in their ability to carry out oxidative phosphorylation. Instead, in proliferating cells, mitochondrial energy pathways are reprogrammed to meet the challenges of macromolecular synthesis and to escape from apoptosis. Tumor initiating cells (TICs) maintain cancer stem cell properties and are known to play significant role in TNBC metastasis. Mitochondrial retrograde regulation (MRR) is a bidirectional communication between mitochondria and nucleus. MRR is triggered by mitochondrial functional demands and it responds in a continuous manner to change metabolic needs of the cell. Using transmitochondrial cybrid (cybrid) technology, we generated different cybrid models under common nuclear backgrounds of benign breast epithelium or TNBC. Mitochondria from cells with different cancer potential such as benign breast epithelium, moderately metastatic and highly metastatic breast cancer cell lines were studied under the common nuclear background to understand MRR-regulated TIC properties and cancer pathways. Using genomic, metabolomic, and proteomic approaches, we confirmed the significance of mitochondrial character in the regulation of epithelial mesenchymal transition (EMT), TIC and metastatic properties. Altogether, our results suggest that MRR is critical in TNBC TIC character and stemness.
Citation Format: Park JH, Jung KH, Sirupangi T, Vithayathil S, Jin F, Putluri V, Piyarathna DWB, Yotnda P, Bhat VB, Sreekumar A, Lewis MT, Coarfa C, Putluri N, Creighton CJ, Wong L-JC, Kaipparettu BA. Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-01-07.
Collapse
Affiliation(s)
- JH Park
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - KH Jung
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - T Sirupangi
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - S Vithayathil
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - F Jin
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - V Putluri
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - DWB Piyarathna
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - P Yotnda
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - VB Bhat
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - A Sreekumar
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - MT Lewis
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - C Coarfa
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - N Putluri
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - CJ Creighton
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - L-JC Wong
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| | - BA Kaipparettu
- Baylor College of Medicine, Houston, TX; Dan L. Duncan Cancer Center-Biostatistics, Baylor College of Medicine, Houston, TX; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Agilent Technologies, Wilmington, DE
| |
Collapse
|